6-K ·Filed May 6, 2026

ARGX

ARGENX SE
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001104659-26-056296
Notable filing: 6-K
Actionable Insight • Neutral

The CEO transition is routine and founder remains as Chair, so no immediate trading catalyst. Monitor any strategic updates from new CEO in upcoming quarters; the share issuance authorization may be used for future financing or acquisitions.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
ARGX ▲ +5.52% at T+60d
NEUTRAL call ✓ call won +5.52% · α vs SPY +1.69% · entry $787.31 → $830.79
Entry anchored
May 6, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α -0.83%
$787.31
settled 5mo ago
T+5d
+1.95%
call +1.95% · α +0.45%
$802.70
settled 5mo ago
T+20d
+3.28%
call +3.28% · α +0.14%
$813.14
settled 4mo ago
T+60d
+5.52%
call +5.52% · α +1.69%
$830.79
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

argenx announced results of its Annual General Meeting and the appointment of Karen Massey as CEO, succeeding founder Tim Van Hauwermeiren who becomes Chair. Shareholders approved all agenda items, including a 10% share issuance authorization. The leadership transition is orderly and the founder remains involved, limiting disruption risk.

Key Facts

  • Karen Massey appointed CEO effective immediately, succeeding founder Tim Van Hauwermeiren.
  • Tim Van Hauwermeiren appointed Chairperson of the Board.
  • All agenda items approved at AGM, including 2025 remuneration report and annual accounts.
  • Authorization to issue up to 10% of outstanding shares for 18 months, with pre-emptive rights exclusion possible.
  • 90.9% of share capital represented at the meeting.

Financial Impact

No direct financial impact disclosed. Share issuance authorization could lead to dilution up to 10%.

dilution

Risk Factors

  • Execution risk under new CEO if strategic direction changes materially.
  • Potential dilution if share issuance authorization is utilized.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-056296
Document: tm2613815d1_6k.htm0001104659-26-056296
Document: 0001104659-26-056296-index-headers.html0001104659-26-056296
Document: 0001104659-26-056296-index.html0001104659-26-056296
Document: 0001104659-26-056296.txt0001104659-26-056296
14 reports for ARGX
Performance horizon
100% Hit rate 8 of 8 directional calls best @ T+60▲ +30.22%Jun 3, 2026
Filters
Rows
Reports for ARGX — sortable, filterable
TypeNow
Sep 10, 2026
22d ago
Institutional Cluster
MIXED ★ 5/10
$984.04 $995.77▲ +1.19%▲ +1.69%$918.23 (−6.69%)
Aug 17, 2026
6w ago
6-K
BULLISH ★ 8/10
$987.84 $1,011.11▲ +2.36%▲ +3.55%$918.23 (−7.05%)
Aug 6, 2026
8w ago
Press Release
BULLISH ★ 7/10
$875.30 $856.94▼ −2.10%▼ −3.31%$918.23 (+4.91%)
Jul 27, 2026
9w ago
6-K
BULLISH ★ 7/10
$888.82 $853.82▼ −3.94%▼ −5.01%$918.23 (+3.31%)
Jul 27, 2026
9w ago
Press Release
BULLISH ★ 7/10
$888.82 $853.82▼ −3.94%▼ −5.01%$918.23 (+3.31%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 5/10
$924.60 $872.58▼ −5.63%▼ −6.10%$918.23 (−0.69%)
Jul 16, 2026
11w ago
Press Release
NEUTRAL ★ 2/10
$857.97 $924.60▲ +7.77%▲ +9.44%$918.23 (+7.02%)
Jun 23, 2026
14w ago
6-K
NEUTRAL ★ 4/10
$853.40 $912.46▲ +6.92%▲ +5.91%$918.23 (+7.60%)
Jun 3, 2026
17w ago
6-K
BULLISH ★ 5/10
$813.14 $862.18▲ +6.03%▲ +9.85%$918.23 (+12.92%)
May 8, 2026
20w ago
Press Release
BULLISH ★ 7/10
$813.28 $776.26▼ −4.55%▼ −4.47%$918.23 (+12.91%)
Showing 10 of 14

US Market Status

Market Open — Closes in 2h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access